(Q36648916)

15 August 2017

Agreement between chromogenic in situ hybridisation (CISH) and FISH in the determination of HER2 status in breast cancer (English)

1 reference

Frédérique Penault-Llorca

15 August 2017

0 references

4

object named as

F Penault-Llorca

0 references

Marie-Christine Mathieu

7

object named as

M C Mathieu

0 references

Anne Vincent-Salomon

8

object named as

A Vincent-Salomon

1 reference

15 August 2017

L Arnould

1

1 reference

15 August 2017

Y Denoux

2

1 reference

15 August 2017

G MacGrogan

3

1 reference

15 August 2017

M Fiche

5

1 reference

15 August 2017

I Treilleux

6

1 reference

15 August 2017

M C Mathieu

7

1 reference

15 August 2017

M O Vilain

9

1 reference

15 August 2017

J Couturier

10

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 May 2003

1 reference

British Journal of Cancer

15 August 2017

1 reference

15 August 2017

88

1 reference

15 August 2017

10

1 reference

15 August 2017

1587-1591

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.bjc.6600943

15 August 2017

0 references

cites work

Determination of HER2 gene amplification by chromogenic in situ hybridization (CISH) in archival breast carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2377115

Real-world performance of HER2 testing--National Surgical Adjuvant Breast and Bowel Project experience

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2377115

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2377115

Integration of trastuzumab into adjuvant systemic therapy of breast cancer: ongoing and planned clinical trials

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2377115

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2377115

Her-2/neu analysis in archival tissue samples of human breast cancer: comparison of immunohistochemistry and fluorescence in situ hybridization

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2377115

Strong correlation between results of fluorescent in situ hybridization and immunohistochemistry for the assessment of the ERBB2 (HER-2/neu) gene status in breast carcinoma

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2377115

Chromogenic in situ hybridization: a practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2377115

Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2377115

Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2377115

HER-2/neu gene amplification compared with HER-2/neu protein overexpression and interobserver reproducibility in invasive breast carcinoma

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2377115

Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2377115

Sensitivity of HER-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2377115

ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2377115

HER-2/neu testing in breast carcinoma: a combined immunohistochemical and fluorescence in situ hybridization approach

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2377115

Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2377115

Evaluating HER2 amplification and overexpression in breast cancer.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2377115

The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2377115

HER2--a discussion of testing approaches in the USA.

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2377115

Quantitative evaluation of HER-2/neu status in breast cancer by fluorescence in situ hybridization and by immunohistochemistry with image analysis

20 September 2018

1 reference

12 December 2020

Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831

1 reference

12 December 2020

Calibration of immunohistochemistry for assessment of HER2 in breast cancer: results of the French multicentre GEFPICS study

1 reference

12 December 2020

Quantitation of HER-2/neu and c-myc gene amplification in breast carcinoma using fluorescence in situ hybridization

1 reference

12 December 2020

Increased HER2 with U.S. Food and Drug Administration-approved antibody

1 reference

12 December 2020

Comparison of fluorescence in situ hybridization and immunohistochemistry for the evaluation of HER-2/neu in breast cancer

1 reference

12 December 2020

Determination of Her-2/Neu status in breast carcinoma: comparative analysis of immunohistochemistry and fluorescent in situ hybridization

1 reference

12 December 2020

HER-2/neu protein expression in breast cancer evaluated by immunohistochemistry. A study of interlaboratory agreement

1 reference

12 December 2020

Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false-positives do not get the message

1 reference

12 December 2020

Laboratory testing for HER2/neu in breast carcinoma: an evolving strategy to predict response to targeted therapy

1 reference

12 December 2020

Identifiers

DOI

10.1038/SJ.BJC.6600943

1 reference

release_udyugo5w2nbm7e2jcmv6g4ebw4

15 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/udyugo5w2nbm7e2jcmv6g4ebw4

24 November 2022

mapped directly with Wikidata item

1 reference

15 August 2017

1 reference